Trial ID 20396 | Maryland Oncology Hematology Trial ID 20396 – Maryland Oncology Hematology

Trial ID 20396

Trial Information - Phase III

DESTINY09: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer

Disease Specifics: HER2+

Protocol ID: D967UC00001

Sponsor: AstraZeneca plc

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Investigator

Ackerman MD, Courtney

Status

OPEN TO ENROLLMENT

Sponsor

AstraZeneca plc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology